Skip to main content

Table 7 Predictive microRNAs - microRNAs involved in response (sensitivity/resistance) to conventional breast cancer therapeutic strategies

From: Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management

Therapy Generic name miRNA Role in response a Evidence Number of patients or type of cells Reference
Hormone therapy       
SERM Tamoxifen miR-375 Sensitivity Preclinical/clinical 2 BC datasets [80]
   miR-342 Sensitivity Preclinical MCF-7 [74]
    Sensitivity Clinical n = 791 [81]
   miR-221/222 Resistance Preclinical MCF-7, T47D, MM-468 [82-84]
SERD Fulvestrant miR-221/222 Resistance Preclinical MCF-7 [85]
AI Letrozole let-7f Sensitivity Preclinical/clinical n = 23 [86]
Targeted therapy       
Monoclonal AB Trastuzumab miR-210 Resistance Preclinical/clinical n = 43 [87]
  FEC miR-125b Resistance Preclinical/clinical n = 56 [89]
    Resistance Preclinical MM-435, SKBR3 [88]
    Resistance Clinical n = 185 [90]
  Taxol/doxo miR-30c Sensitivity Preclinical T47D, MCF-7, MM-231 [91,92]
  Taxol miR-21 Resistance Preclinical MM-468 [9,93]
  Radiotherapy miR-34a Sensitivity Preclinical T47D, MCF-7, MM-231 [95,96]
  1. aMicroRNA (miRNA) overexpression leads to an increase in resistance or sensitivity to the mentioned therapy (referred to as ‘resistance’ or ‘sensitivity’, respectively). AB, antibody; AI, aromatase inhibitor; BC, breast cancer; Doxo, doxorubicin; FEC, fluorouracil, epirubucin and cyclophosphamide; SERD, selective estrogen receptor downregulator; SERM, selective estrogen receptor modulator; Taxol, paclitaxel.